Kirstine J Bell, Samantha J Lain, Lindsay Stevens, Maria E Craig, Kim C Donaghue, Natasha Nassar
{"title":"澳大利亚新南威尔士州儿童1型糖尿病诊断中与糖尿病酮症酸中毒相关的18年发病率、健康结局和费用","authors":"Kirstine J Bell, Samantha J Lain, Lindsay Stevens, Maria E Craig, Kim C Donaghue, Natasha Nassar","doi":"10.1155/pedi/2550952","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Diabetic ketoacidosis (DKA) is a life-threatening complication of type 1 diabetes (T1D). We determined the incidence, trends, cost and characteristics of children with and without DKA at T1D diagnosis and association with DKA readmissions. <b>Methods:</b> Children aged <16 years with T1D and residing in New South Wales, Australia, were identified from population-based hospital records (Admitted Patient Data Collection; APDC) for 2002-2019. Diagnoses of T1D and DKA were identified using ICD10 codes. Costs were determined using the 'Australian Refined-Diagnosis Related Group' (AR-DRG) code multiplied by the cost weight and National Efficient Price for the admission year. Associations were assessed using Chi-squared analyses and multivariate regression. <b>Results:</b> A total of 5832 children with T1D were identified, and 36% had DKA at diagnosis. The proportion with DKA at diagnosis was 34.4% in 2002-2003 and 41.0% in 2018-2019, with limited evidence to support a meaningful change over time (Cochrane-Armitage test-for-trend, <i>p</i>=0.062). DKA at diagnosis was associated with age <2 years, lower socio-economic status (SES) and rural/regional areas. DKA at diagnosis was also associated with an increased risk of readmission(s) for DKA (odds ratio [OR]: 1.35 [95% confidence interval [CI] 1.23, 1.49]). DKA doubled the costs/person, considering all available follow-up ($20,571 [interquartile range: $10,825, $37,845] vs. $9743 [$4980, $18,287]). <b>Conclusion:</b> DKA at diagnosis of T1D is a common and expensive health issue in Australia, with the rate of DKA at diagnosis not improving over the last two decades. Effective strategies are needed to improve health outcomes and reduce the economic burden.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"2025 ","pages":"2550952"},"PeriodicalIF":5.6000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303653/pdf/","citationCount":"0","resultStr":"{\"title\":\"Eighteen-Year Incidence, Health Outcomes and Costs Associated With Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Children in NSW, Australia.\",\"authors\":\"Kirstine J Bell, Samantha J Lain, Lindsay Stevens, Maria E Craig, Kim C Donaghue, Natasha Nassar\",\"doi\":\"10.1155/pedi/2550952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Diabetic ketoacidosis (DKA) is a life-threatening complication of type 1 diabetes (T1D). We determined the incidence, trends, cost and characteristics of children with and without DKA at T1D diagnosis and association with DKA readmissions. <b>Methods:</b> Children aged <16 years with T1D and residing in New South Wales, Australia, were identified from population-based hospital records (Admitted Patient Data Collection; APDC) for 2002-2019. Diagnoses of T1D and DKA were identified using ICD10 codes. Costs were determined using the 'Australian Refined-Diagnosis Related Group' (AR-DRG) code multiplied by the cost weight and National Efficient Price for the admission year. Associations were assessed using Chi-squared analyses and multivariate regression. <b>Results:</b> A total of 5832 children with T1D were identified, and 36% had DKA at diagnosis. The proportion with DKA at diagnosis was 34.4% in 2002-2003 and 41.0% in 2018-2019, with limited evidence to support a meaningful change over time (Cochrane-Armitage test-for-trend, <i>p</i>=0.062). DKA at diagnosis was associated with age <2 years, lower socio-economic status (SES) and rural/regional areas. DKA at diagnosis was also associated with an increased risk of readmission(s) for DKA (odds ratio [OR]: 1.35 [95% confidence interval [CI] 1.23, 1.49]). DKA doubled the costs/person, considering all available follow-up ($20,571 [interquartile range: $10,825, $37,845] vs. $9743 [$4980, $18,287]). <b>Conclusion:</b> DKA at diagnosis of T1D is a common and expensive health issue in Australia, with the rate of DKA at diagnosis not improving over the last two decades. Effective strategies are needed to improve health outcomes and reduce the economic burden.</p>\",\"PeriodicalId\":19797,\"journal\":{\"name\":\"Pediatric Diabetes\",\"volume\":\"2025 \",\"pages\":\"2550952\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303653/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/pedi/2550952\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/pedi/2550952","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Eighteen-Year Incidence, Health Outcomes and Costs Associated With Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Children in NSW, Australia.
Aim: Diabetic ketoacidosis (DKA) is a life-threatening complication of type 1 diabetes (T1D). We determined the incidence, trends, cost and characteristics of children with and without DKA at T1D diagnosis and association with DKA readmissions. Methods: Children aged <16 years with T1D and residing in New South Wales, Australia, were identified from population-based hospital records (Admitted Patient Data Collection; APDC) for 2002-2019. Diagnoses of T1D and DKA were identified using ICD10 codes. Costs were determined using the 'Australian Refined-Diagnosis Related Group' (AR-DRG) code multiplied by the cost weight and National Efficient Price for the admission year. Associations were assessed using Chi-squared analyses and multivariate regression. Results: A total of 5832 children with T1D were identified, and 36% had DKA at diagnosis. The proportion with DKA at diagnosis was 34.4% in 2002-2003 and 41.0% in 2018-2019, with limited evidence to support a meaningful change over time (Cochrane-Armitage test-for-trend, p=0.062). DKA at diagnosis was associated with age <2 years, lower socio-economic status (SES) and rural/regional areas. DKA at diagnosis was also associated with an increased risk of readmission(s) for DKA (odds ratio [OR]: 1.35 [95% confidence interval [CI] 1.23, 1.49]). DKA doubled the costs/person, considering all available follow-up ($20,571 [interquartile range: $10,825, $37,845] vs. $9743 [$4980, $18,287]). Conclusion: DKA at diagnosis of T1D is a common and expensive health issue in Australia, with the rate of DKA at diagnosis not improving over the last two decades. Effective strategies are needed to improve health outcomes and reduce the economic burden.
期刊介绍:
Pediatric Diabetes is a bi-monthly journal devoted to disseminating new knowledge relating to the epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes in childhood and adolescence. The aim of the journal is to become the leading vehicle for international dissemination of research and practice relating to diabetes in youth. Papers are considered for publication based on the rigor of scientific approach, novelty, and importance for understanding mechanisms involved in the epidemiology and etiology of this disease, especially its molecular, biochemical and physiological aspects. Work relating to the clinical presentation, course, management and outcome of diabetes, including its physical and emotional sequelae, is considered. In vitro studies using animal or human tissues, whole animal and clinical studies in humans are also considered. The journal reviews full-length papers, preliminary communications with important new information, clinical reports, and reviews of major topics. Invited editorials, commentaries, and perspectives are a regular feature. The editors, based in the USA, Europe, and Australasia, maintain regular communications to assure rapid turnaround time of submitted manuscripts.